Yamopharma

Yamo Pharmaceuticals is developing L1-79, an oral therapy for the core social-interaction symptoms of Autism Spectrum Disorder. FDA Fast Track. Phase 2 data.

Is Yamopharma yours? Feature it on the map for $49 a month, in front of everyone who opens it.

Are you a founder of Yamopharma and want your details removed? Write to us and we remove them within 72 hours.